Affiliation:
1. Laboratory of neurophysiology, Biology Department, University of the Balearic Islands, Health Research Institute of the Balearic Islands (IdISBa), and CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122 Palma de Mallorca, Spain
2. Research Group on Community Nutrition and Oxidative Stress (NUCOX), Health Research Institute of the Balearic Islands (IdISBa), and CIBEROBN (Physiopathology of Obesity and Nutrition), E-07122 Palma de Mallorca, Balearic Islands, Spain
Abstract
Background:
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic
liver disease worldwide, directly related to the progressive increase in body weight and obesity. The accumulation
of lipids in patients with NAFLD contributes to the development of insulin resistance, inflammatory response and
oxidative stress in hepatocytes and alteration of the circulating lipid and glycaemic profile. However, to date,
there are no effective pharmacological treatments for patients with NAFLD. Lifestyle changes and dietary modifications
aimed at weight loss are the best current alternatives; therefore, new approaches should be considered.
Resveratrol, a natural polyphenol of the stilbene group, is a potential candidate for the management of NAFLD
for its anti-inflammatory, antioxidant properties, and calorie restriction-like effects.
Methods:
In this review, the available information on the potential therapeutic effects of resveratrol on NAFLD,
found mainly in animal models and in some clinical trials, is summarizes.
Results:
In vitro and animal model studies have shown beneficial effects of resveratrol treatment on NAFLD.
Resveratrol reduces the hepatic accumulation of lipids and improves lipid and glycaemic metabolism. Some of
the mechanisms of action are the signalling pathways of AMP-activated protein kinase, sirtuin 1 and nuclear
factor κB. However, the results obtained in clinical trials are inconclusive.
Conclusion:
Although preclinical trials have shown promising results of resveratrol against NALFD, the lack of
clear results in clinical trials makes it necessary to conduct more studies with a larger number of patients and for a
longer time.
Funder
Fundació La Marató de TV3
Institute of Health Carlos III
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献